EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Selenium and Vitamin E Cancer Prevention Trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration

Marco Vinceti iD, Cathee Till iD, Phyllis J Goodman iD, Tommaso Filippini iD, Kenneth J Rothman, Ian M Thompson

American Journal of Epidemiology · 12.08.2026

DOI: 10.1093/aje/kwag189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, online erschienen am 12.08.2026. Verfasst von Marco Vinceti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Department of Biomedical, Metabolic and Neural Sciences, University of…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potential for trace amounts of selenium supplements to prevent prostate cancer and other neoplasms was studied in the Selenium and Vitamin E Prevention Trial, a randomized trial conducted in North America for 7-12 years. A total of 34 887 eligible men aged 55 or older were assigned to take either 200 μg selenium from L-selenomethionine, 400 IU vitamin E, both selenium and vitamin E, or placebo. The trial was stopped for futility and concerns about adverse effects. Subsequently, we used incidence and mortality data from Medicare through 2019 and the National Death Index through 2024 to investigate the extent to which selenium administration was associated with increased long-term risk of cancer and neurodegenerative disease, during 341 697 person-years of follow-up. Lung cancer showed little increased risk. Associations were near null for leukemia, non–Hodgkin lymphoma, and Parkinson’s disease, and there was a lower risk for melanoma and colorectal cancer. In contrast, we found a higher risk for Hodgkin lymphoma, multiple myeloma, and amyotrophic lateral sclerosis, which has been associated with selenium overexposure in some nonexperimental studies. Though these latter associations were based on few cases, they were consistent with findings from a range of other studies, possibly indicating long–term adverse effects of this organic selenium compound (registration no. NCT00006392).

Schlagwörter

Stichwörter der Autor:innen

amyotrophic lateral sclerosiscancerrandomized controlled trialsecondary analysisseleniumselenium supplementation

Autor:innen und Institutionen

  • Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States.
  • Fred Hutchinson Cancer Center, Seattle, WA, United States.
  • School of Public Health, University of California Berkeley, Berkeley, CA, United States.
  • University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

ORCID-Profile: Marco Vinceti, Cathee Till, Phyllis J Goodman, Tommaso Filippini

Zitieren

APA

Vinceti, M., Till, C., Goodman, P. J., Filippini, T., Rothman, K. J., & Thompson, I. M. (2026). The Selenium and Vitamin E Cancer Prevention Trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwag189

Vancouver

Vinceti M, Till C, Goodman PJ, Filippini T, Rothman KJ, Thompson IM. The Selenium and Vitamin E Cancer Prevention Trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration. American Journal of Epidemiology. 2026. doi:10.1093/aje/kwag189

BibTeX
@article{Vinceti2026,
  author = {Vinceti, Marco and Till, Cathee and Goodman, Phyllis J and Filippini, Tommaso and Rothman, Kenneth J and Thompson, Ian M},
  title = {The Selenium and Vitamin E Cancer Prevention Trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration},
  journal = {American Journal of Epidemiology},
  year = {2026},
  doi = {10.1093/aje/kwag189}
}
Kostenlos starten →